Former Yankees Pitcher Tanyon Sturtze Predicts MLB Lockout During Exclusive Interview on Biz Talk Today TV's Franchise Value

Sturtze joins host Shana Orczyk Sissel to deliver a candid warning about baseball's looming labor dispute, the salary-cap battle and the financial risks facing younger players.

WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- CrossCheck Media Inc., parent company of Biz Talk Today TV (BTT), today announced the release of a special episode of its sports-business program, Franchise Value, featuring former Major League Baseball pitcher Tanyon Sturtze, who delivered a stark warning about the possibility of another MLB lockout as the league approaches a critical collective bargaining deadline.

In an exclusive conversation with host Shana Orczyk Sissel, CEO and Founder of Banríon Capital Management and author of the forthcoming book Tough Minded, Sturtze discussed the escalating tensions between Major League Baseball's owners and players, offering a rare insider's perspective on the financial and personal consequences of a prolonged labor dispute.

"Unfortunately, it's definitely coming," Sturtze said of a potential lockout. "I'm on the player's side, but that's going to be a tough battle for them."

The comments come as Major League Baseball approaches the December 1 expiration of its current collective bargaining agreement, with disagreements over a potential salary cap, payroll requirements and player compensation threatening to disrupt the sport's future.

Sturtze, a 12-year MLB veteran who played for the New York Yankees, Tampa Bay Rays and Los Angeles Dodgers, drew upon his firsthand experience during baseball's 1994–95 labor dispute to explain why younger players could face the greatest financial consequences.

"The younger kids, they're gonna have a tough time if they do get locked up," Sturtze warned.

The episode also explores one of baseball's most controversial financial questions: Does spending more money actually produce championship teams?

Having experienced both the financial limitations of a smaller-market franchise and the enormous resources of the New York Yankees, Sturtze challenged the belief that payroll size alone determines success.

"Just because they have big payrolls doesn't mean that they have a good team," Sturtze told Sissel.

Beyond the potential labor dispute, the interview examines the business realities of professional baseball, including player salaries, the financial vulnerabilities of young athletes, clubhouse chemistry, career-ending injuries and the importance of protecting wealth after retirement.

Sturtze, now an insurance specialist with Hotaling Insurance, also discusses his transition from professional baseball into the insurance industry and the challenges athletes face when their playing careers end.

"I still need a job. I still need a paycheck," Sturtze said, emphasizing that even a lengthy professional sports career does not guarantee lifetime financial security.

The special episode reinforces Franchise Value's commitment to delivering insightful conversations with athletes, executives and financial professionals about the business decisions shaping professional sports.

The complete episode featuring Tanyon Sturtze is now available on Biz Talk Today TV and the CrossCheck Media YouTube channel.

About Franchise Value

Franchise Value is a sports-business program produced by CrossCheck Media Inc. and distributed through Biz Talk Today TV. Hosted by Shana Orczyk Sissel, CEO and Founder of Banríon Capital Management, the program examines the financial forces driving professional sports, including franchise valuations, ownership structures, private equity, athlete compensation, media rights and the economics of professional leagues.

About Biz Talk Today TV

Biz Talk Today TV (BTT), a CrossCheck Media Inc. property, is a global business and financial news network delivering original programming focused on Wall Street, economics, investing, public policy and the business of sports. BTT reaches audiences worldwide through major streaming platforms, including Apple TV, Roku, Amazon Fire TV, Samsung TV, LG TV, Whale TV and YouTube, alongside its dedicated mobile application and global audio distribution network.

Media Contact

CrossCheck Media Inc.

Naomi Knight

Biz Talk Today TV | Franchise Value

Media Relations | 202-294-3376

Website: https://www.youtube.com/@CrossCheckMedia

SOURCE CrossCheck Media Inc.

Share this article

Capacity Sports Group Bolsters Executive Team, Names Mike Kenney Chief Revenue Officer

Former Ripken Baseball CEO joins a growing leadership team supporting Capacity's expansion across youth sports, events and destinations

INDIANAPOLIS, Oct. 21, 2026 /PRNewswire/ -- Capacity Sports Group, a leading youth sports company that brings together proven operators, established event brands and sports destinations, today announced the appointment of Mike Kenney as chief revenue officer. The former CEO of Ripken Baseball brings decades of experience growing sports businesses, developing programming and building commercial partnerships as Capacity expands across sports and markets.

Kenney's appointment follows several additions to Capacity's team since the spring, including chief operating officer Dan LeBlanc, senior vice president of M&A Surry Wood, Chief of Staff Kristen Ajamie and Director of Corporate Development John Vardzel. They join an established leadership team that includes President Blake Hibler.

"We're building Capacity Sports Group to become the leading platform in youth sports, and that starts with exceptional operators who know how to deliver for athletes and families," said Ken Kocher, CEO of Capacity Sports Group. "Mike brings a proven track record of growing sports businesses, building brands and developing valuable partnerships. He joins leaders who have spent more than 20 years building and running the businesses now part of Capacity."

As chief revenue officer, Kenney will help advance Capacity's revenue strategy, working with its businesses to develop commercial partnerships and opportunities for growth across events, facilities and programming.

Kenney served as CEO of Ripken Baseball from 2019 to 2024, overseeing strategic initiatives, facility improvements, marketing and programming. During his tenure, the company launched Ripken Select and All-Ripken Games and secured a seven-figure partnership with a global athletic apparel company. Previously, Kenney spent more than a decade with the Harlem Globetrotters as executive vice president. He helped double domestic tour revenue over that period, secured the largest revenue partnership in the company's history and led marketing, public relations and audience development initiatives. His earlier career included roles with Comcast Spectacor.

"What drew me to Capacity was the experience throughout the company and the opportunity to build something together," said Kenney. "These businesses have earned the trust of athletes, coaches and families over many years. We can help them reach more teams, develop new programming and create partnerships that make their events and facilities even stronger. I'm excited to get to work alongside the people who know those businesses best."

Capacity was introduced in January 2026 following the merger of Prep Baseball and Bullpen Ventures, connecting scouting, showcases, media and player development with tournament programming and venue operations. Its approach combines the relationships and expertise of established sports businesses with resources they can share across the company.

Since its launch, Capacity has added Play9 Sports, United Sports, YSC Sports, Sideline Soccer Solutions, Flag Football Life, West Chester Flag Football, BNA Athletes and Ryze Hoops, expanding its network of multisport facilities and programming across baseball, softball, soccer, flag football, lacrosse and basketball.

The company also recently expanded its multisport operations at LakePoint Sports near Atlanta, building on Prep Baseball's tournament presence there since 2019. The addition of Publix Fields and operations at the 170,000-square-foot Champions Center Indoor Pavilion creates opportunities to bring more sports and events to the nationally recognized destination.

Capacity's strategic focus spans baseball, softball, soccer, lacrosse, volleyball and flag football. As its network grows, the company aims to preserve the identities and relationships that distinguish its businesses while supporting shared expectations for quality, safety and accountability.

About Capacity Sports Group

Capacity Sports Group brings together experienced youth sports operators, established event brands and quality sports facilities to create experiences that athletes, families, coaches and communities trust. Introduced in January 2026 following the merger of Prep Baseball and Bullpen Ventures, Capacity connects venue operations, tournaments, teams, scouting and media to support athletes throughout their development. Its family of businesses includes Prep Baseball, Bullpen Tournaments, Prep Baseball Tournaments, Top Tier, Play9 Sports, United Sports, YSC Sports, Sideline Soccer Solutions, Flag Football Life, LakePoint Sports, West Chester Flag Football, BNA Athletes and Ryze Hoops. Its vision is to raise the standard of amateur sports for every athlete and everyone invested in their journey. Learn more at capacitysportsgroup.com.

Press Contact:

Eric Nemeth

[email protected]

www.capacitysportsgroup.com/

SOURCE Capacity Sports Group

Share this article

Central Holidays Invites Travelers to Discover the Warmth and Wonders of Central & South America with Exclusive Added-Value Travel Offer

-- Award-winning travel brand showcases immersive, customizable journeys to

Argentina, Brazil, Costa Rica, Peru and Ecuador, featuring a complimentary

guided experience valued at up to $399 per person --

MOONACHIE, N.J., Oct. 21, 2026 /PRNewswire/ -- As travelers look to trade colder days this fall and winter for sunshine, spectacular landscapes, and new adventures, Central Holidays is shining the spotlight on the amazing diversity of Central and South America, inviting travel advisors and their clients to discover a world of unforgettable experiences with the ultimate in destination expertise and an exclusive added-value travel offer. The award-winning travel brand, renowned for more than five decades of destination specialists delivering meticulously crafted travel programs, is offering a complimentary guided experience valued at up to $399 per person on qualifying bookings to Argentina, Brazil, Costa Rica, Peru, and Ecuador.

From the rhythm and romance of Buenos Aires and Rio de Janeiro to the lush rainforests of Costa Rica, the ancient wonders of Peru, and the remarkable biodiversity of Ecuador, Central Holidays presents a captivating collection of travel opportunities that pair some of the world's most extraordinary destinations with its signature approach to personalized, affordable-luxury travel.

For travelers seeking an escape from the colder months in North America, these destinations offer an enticing combination of seasonal warmth, cultural discovery, outdoor adventure, and authentic local experiences. While weather varies by region and elevation, much of South America welcomes its warmer season as winter arrives in the United States, creating exceptional opportunities for travelers to discover these remarkable countries from a different seasonal perspective.

"Central and South America offer an incredible range of travel experiences, and that's what makes these destinations so exciting for travel advisors and their clients," said Adam Greis, General Manager of Central Holidays. "Within this extraordinary region, travelers can discover everything from fascinating ancient civilizations and magnificent natural wonders to sophisticated cities, spectacular beaches, and incredible culinary traditions. Our destination specialists bring all these elements together to create personalized journeys that reflect each traveler's interests. With this special offer, we're adding even more value while giving advisors an outstanding opportunity to introduce their clients to destinations they may not have previously considered."

Five Extraordinary Destinations. Endless Possibilities.

Central Holidays' expansive Central and South America portfolio brings together iconic attractions and immersive experiences that reveal the unique personality of each destination.

- Argentina – A World of Passion, Culture and Natural Wonders

From the European-inspired boulevards and tango traditions of Buenos Aires to the breathtaking beauty of Patagonia and the thundering cascades of Iguazú Falls, Argentina delivers an irresistible blend of cosmopolitan sophistication and beautiful naturescapes. Travelers can explore renowned wine regions, savor authentic Argentine cuisine, and discover the country's rich cultural heritage through thoughtfully designed experiences.

- Brazil – Where Nature, Culture and Celebration Come Together

Brazil captivates from the start with its dazzling combination of golden beaches, tropical landscapes, and lively energy. From the iconic sights of Rio de Janeiro, including Sugarloaf Mountain and Christ the Redeemer, to the spectacular Brazilian side of Iguazú Falls, the country's vibrant music, and culinary traditions, Central Holidays offers opportunities to experience the distinctive spirit of this remarkable destination.

- Costa Rica – A Tropical Paradise for Nature Lovers and Adventure Seekers

For travelers dreaming of lush landscapes and outdoor adventure, Costa Rica offers an enchanting escape into one of the world's most biodiverse destinations. Discover verdant rainforests, magnificent volcanoes, wildlife-rich national parks, and inviting Pacific and Caribbean coastlines. From exhilarating adventures to relaxing nature retreats, Costa Rica presents a wealth of opportunities for families, couples, and groups seeking meaningful connections with the great outdoors and beyond.

- Peru – Ancient Civilizations, Culinary Treasures, and Breathtaking Landscapes

Few destinations combine history, culture, natural beauty, and world-class gastronomy quite like Peru. Travelers can follow in the footsteps of the Incas through the Sacred Valley and legendary Machu Picchu, discover the vibrant culinary scenes of Lima and Cusco, and savor innovative cuisine and authentic regional flavors that have earned Peru international acclaim as a premier culinary destination. Central Holidays' destination specialists bring Peru's extraordinary heritage and rich culinary traditions to life through immersive experiences that go far beyond conventional sightseeing.

- Ecuador – Extraordinary Biodiversity and Authentic Cultural Encounters

Small in size yet remarkable in diversity, Ecuador offers a fascinating combination of colonial cities, dramatic Andean landscapes, colorful indigenous markets, and extraordinary wildlife experiences. Quito was recognized in the 2026 World Travel Awards (WTA) as South America's Leading City Destination and Leading Cultural City Destination, further highlighting its rich cultural heritage, historic charm, and growing appeal as a must-visit destination in South America. From the historic heart of Quito to the natural wonders of the Galápagos Islands, Ecuador invites travelers to discover a destination filled with memorable encounters and striking contrasts.

Exclusive Added Value: Complimentary Guided Experience Worth Up to $399 Per Person

To encourage travelers to explore the region, Central Holidays is featuring a special Fall 2026 Central & South America Offer that includes a complimentary guided experience valued at up to $399 per person on qualifying vacations to Argentina, Brazil, Costa Rica, Peru, or Ecuador.

The added-value experience offers travel advisors another compelling selling point when recommending these destinations, enhancing the overall vacation experience while providing additional value for their clients.

Travel advisors can explore the promotion and applicable booking details via this link.

Helping Travel Advisors Turn Destination Expertise into Business Opportunities

With Central and South America's extraordinary diversity comes the need for knowledgeable planning, carefully coordinated travel arrangements, and trusted local expertise. Central Holidays works alongside travel advisors as an extension of their own teams, providing the specialized destination knowledge and comprehensive planning resources needed to create seamless, memorable vacations.

From customized independent travel and private guided experiences to multigenerational vacations, special-interest groups, and fully tailored group journeys, the company's destination specialists help advisors bring even the most intricate travel requests to life. Central Holidays' experienced professionals coordinate accommodations, transportation, sightseeing, and other essential travel arrangements, supported by established destination partnerships and local resources.

For group travel planners, the region offers particularly exciting possibilities. Culinary and wine enthusiasts can discover Argentina's celebrated vineyards, nature-focused groups can explore Costa Rica's extraordinary biodiversity, and cultural or educational organizations can build immersive journeys around Peru's ancient civilizations or Ecuador's remarkable heritage.

By bringing together destination expertise, itinerary development, customization, and comprehensive travel planning, Central Holidays helps advisors confidently expand their offerings into markets where specialized knowledge and reliable local connections can make all the difference.

"Travel advisors shouldn't have to become experts in every destination around the world to deliver extraordinary experiences for their clients," added Greis. "That's where our team comes in. We provide the destination insight, planning expertise, and trusted local relationships that help advisors confidently develop highly personalized travel programs. Whether it's a couple planning their life-list, dream experience or an organization bringing together a group of travelers with shared interests, we work behind the scenes to make the advisor shine. Their success is our success, and that's a partnership we've believed in since Central Holidays was founded."

A World of Discovery, Backed by More Than 50 Years of Experience

Established in 1972, Central Holidays continues to build upon its longstanding reputation for creating thoughtfully planned travel experiences that combine exceptional value, personalized service, and authentic destination discovery.

With its extensive portfolio throughout Central and South America, the company invites travel advisors and group planners to explore new opportunities to grow their businesses while introducing travelers to destinations filled with inspiration, adventure, and lasting memories.

For additional information about Central Holidays' Central and South America programs and the current special offer, travel advisors can contact [email protected] or call 1-800-935-5000. Advisors interested in expanding their business with Central Holidays can contact Margie Bell, Travel Industry Sales Vice President, at [email protected].

1-800-Flowers.com named exclusive Official Floral Partner of the 2026 TCS New York City Marathon

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- 1-800-Flowers.com® today announced a partnership with New York Road Runners (NYRR), the nonprofit that "runs" New York City, naming the brand the exclusive Official Floral Partner of the 2026 TCS New York City Marathon, one of 60 annual adult and youth races the nonprofit produces annually.

The collaboration brings together two milestone celebrations: the 50th anniversary of the floral authority 1-800-Flowers.com, which started as a single flower shop in Manhattan in 1976, and the 50th anniversary of the New York City Marathon's iconic 5-boro course that was first run in 1976 to celebrate the nation's Bicentennial and uplift the city. Together, they will recognize the dedication, determination and achievements of runners throughout marathon week.

As the exclusive Official Floral Partner, 1-800-Flowers.com will create and provide the bouquets presented to the TCS New York City Marathon men's and women's open and wheelchair division champions at the finish line. Beautifully designed and presented in custom-branded wraps, the bouquets will celebrate the athletes' extraordinary accomplishments and #GiveThemTheirFlowers for completing the world's most iconic sporting event.

"In sports, there's no higher compliment than to give someone their flowers, and there's no better place to do it than the finish line of the TCS New York City Marathon," said Adolfo Villagomez, CEO, 1-800-Flowers.com, Inc. "1-800-Flowers.com opened our first flower shop in Manhattan in 1976, the same year runners first raced through all five boroughs, so celebrating our 50th anniversaries alongside New York Road Runners feels like a true hometown moment. We're proud to honor the champions in all of us as we celebrate the determination of every runner who takes on the journey of 26.2 miles."

"Every runner who takes on the TCS New York City Marathon deserves their flowers, and we're thrilled to welcome 1-800-Flowers.com as our Official Floral Partner as we celebrate the 50th anniversary of the New York City Marathon's 5-boro course," said Christine Burke, New York Road Runners Chief Commercial Officer. "For 50 years, 1-800-Flowers.com has helped mark life's most meaningful moments, making them the perfect partner to help us recognize the nearly 60,000 runners, from professional athletes to Final Finishers, whose dedication and perseverance define the TCS New York City Marathon."

Celebrating Marathon Week With Flowers

Created in collaboration with New York Road Runners, the exclusive, limited-edition TCS New York City Marathon 26.2 Bouquet gives runners, spectators, friends and family a meaningful way to commemorate the race and recognize the runner in their lives. The bouquet is available now on 1-800-Flowers.com through November 6 for $79.99 and includes a free limited-edition TCS New York City Marathon tote bag, while supplies last.

The partnership will also bring fresh floral arrangements to select New York Road Runners pre-race events, adding celebratory touches to key moments throughout Marathon Week and leading up to race day.

The 2026 TCS New York City Marathon taking place Sunday, Nov.1, 2026, is one of the most inclusive and accessible sporting events in the world, bringing together nearly 60,000 participants and more than 2 million spectators for a 26.2-mile journey across the five boroughs.

About 1-800-Flowers.com

For 50 years, 1-800-Flowers.com has offered truly original floral arrangements, plants, and unique gifts to celebrate birthdays, anniversaries, everyday occasions, and seasonal holidays, and to deliver comfort during times of grief. Backed by a caring team obsessed with service, 1-800-Flowers.com provides customers with thoughtful ways to express themselves and connect with the most important people in their lives.

FLWS-18F

SOURCE 1-800-Flowers.com

Share this article

The limited-edition lineup brings Dusen Dusen's playful aesthetic to Hanna Andersson's iconic sleepwear, everyday apparel and accessories for babies, kids and adults

PORTLAND, Ore., Oct. 21, 2026 /PRNewswire/ -- Hanna Andersson, the trusted children's apparel and pajama brand celebrated as the "Champions of Childhood," today announced a second limited-edition collaboration with acclaimed homegoods and lifestyle brand Dusen Dusen. Following the success of their first collection, the new assortment of sleepwear, apparel and accessories for babies, kids and adults is available starting today to Hanna Rewards members, with the full collection opening to everyone on October 22.

Where the debut collection was built around Dusen Dusen's bold stripes, this season is all about the dot. Graphic polka dots run throughout the designs, alongside familiar Dusen Dusen motifs like the brand's iconic Everybody Face and Cloud, both recognizable from some of its best-selling home and apparel designs. Each piece pairs that distinctive approach to color, scale and pattern with the comfort and quality families count on from Hanna Andersson.

"At Hanna, we've always embraced bold color and playful prints, so there's a natural connection with Dusen Dusen," shares Kara Carter, Chief Product Officer at Hanna Andersson. "Their use of color and pattern brings such a fresh, joyful perspective to our collections. Our first collaboration featured stripes, and we love how this next chapter evolves into polka dots. We've brought Dusen Dusen's design point of view to some of our most beloved Hanna styles, from pajamas to sweatshirts and jackets. The collection celebrates the best of both brands, combining Dusen Dusen's unmistakable aesthetic and Hanna's commitment to quality, comfort and designing with kids at the center of everything we do."

The collection arrives just in time for cozy season, with pieces made for sleeping, lounging, layering and everyday wear. Highlights include Women's Polka Dot Poplin Pajama Sets (in shorts and pants), Kids Polka Dot Long Johns, socks for the whole family, sweatshirts for adults and kids, a baby sweatsuit and kids' jackets. The full collection is available at Hanna Andersson, with a selection of styles also available through Dusen Dusen.

"Last year's collection was such a fun opportunity to bring the Dusen Dusen world into a brand I've loved for a long time," says Van Dusen. "For the second collection, we wanted to keep that same sense of play but explore a different visual language. Last year was really about stripes, and this year is all about dots. I was pregnant with my second son while we were working on it, so I was thinking a lot about clothes that feel joyful and special but that kids can actually live in. Now having two boys who basically live in Hanna Andersson makes the collaboration feel even more personal."

To celebrate the partnership's return, Hanna Andersson has restocked select favorites from the original Hanna Andersson x Dusen Dusen collection on hannaandersson.com, giving families another chance to shop the styles they loved.

Select styles from the original collection are also available to shop through the MoMA Design Store and SFMOMA Museum Store, introducing Hanna's signature comfort and quality to new audiences who appreciate thoughtful design.

Together, the new collection and returning favorites offer a colorful wardrobe for the whole family.

For more information or to shop online, visit hannaandersson.com or dusendusen.com and follow along on Instagram, TikTok, Pinterest and Facebook.

About Hanna Andersson

Hanna Andersson has been outfitting the adventure of childhood for over 40 years. It started with a Swedish mom in Portland, Oregon who set out to create pajamas and clothing with the same high quality she had grown up with in her native Sweden. From the original matching family PJs in legendary organic cotton to the comfiest styles for play and the softest, safest baby essentials—Hannas are made to last. A true pioneer in sustainability, Hanna Andersson is known for "Hanna-Me-Down quality" which promotes circularity and longevity, while reducing waste. It is the #1 resold children's brand—and their commitment to the planet continues to grow. Made to play. Made to last.

About Dusen Dusen

Dusen Dusen is a Brooklyn-based textile and home goods line that includes bedding, throws, pillows, towels, and clothing. Founded by Ellen Van Dusen in 2010 originally as a womenswear label, Dusen Dusen develops seasonal collections inspired by fine art, commercial and naïve design, as well as the brain's reaction to color, movement, and contrast. In 2015, the brand expanded with the launch of Dusen Dusen Home. Known for its bold and original prints, Dusen Dusen has collaborated with a wide range of celebrated international brands including Uniqlo, Keds, and West Elm, to name a few. Ellen Van Dusen was born and raised in Washington, DC and currently resides in Brooklyn, NY. 

Media Contact

ICR

[email protected] 

SOURCE Hanna Andersson

Share this article

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Equity Insider News Commentary - Three of the largest names in U.S. aerospace and defense reported third-quarter results on Tuesday, and all three raised their full-year guidance. Two of them reported record backlogs, including a $340 billion order book at one contractor that counts $164 billion of defense work. The reports open a busy stretch for the sector, with two more major contractors scheduled to report over the next eight days, and they land against a backdrop of rising defense commitments from NATO allies and a record U.S. budget request, even as Washington operates on a stopgap funding bill. Active Companies from around the markets with current developments this week include: RTX Corporation (NYSE: RTX), Northrop Grumman Corporation (NYSE: NOC), GE Aerospace (NYSE: GE), Lockheed Martin Corporation (NYSE: LMT), L3Harris Technologies, Inc. (NYSE: LHX).

The spending story starts with the targets governments have set. At the 2025 NATO Summit in The Hague, Allies committed to investing 5% of GDP annually on defence by 2035, with at least 3.5% of GDP going to core defence requirements. In Washington, the president's fiscal year 2027 budget request came in at $1.5 trillion, which the Pentagon described in April as the largest request in history, and it seeks funding to expand production capacity and build stockpiles for Patriot, Terminal High Altitude Area Defense and precision strike missiles, among other weapons.

A request is not an appropriation. For now, the government is funded by a continuing resolution signed on September 2 that runs through December 11, and according to the Congressional Research Service, the measure bars the Department of Defense from using that funding to accelerate production rates above those sustained with fiscal year 2026 funds. That puts more weight on the contracts companies already hold, and on the backlogs those contracts build, as this earnings season unfolds.

Investors did not treat Tuesday's three reports the same way. Northrop Grumman shares rose 4.57% to $534.00 and RTX gained 0.64% to $193.34, while GE Aerospace fell 3.67% to $299.87 even after raising its guidance, according to Stock Analysis data.

A raised forecast does not guarantee a higher share price, and the chart can show how investors are leaning before the next headline lands. Readers who want to learn to read those signals can get the free Knowledge is Power guide from Stock Preachers at equity-insider.com/.

In other industry developments and happenings in the market this week include:

RTX Corporation (NYSE: RTX)

RTX reported third-quarter sales of $25.0 billion, up 11% from a year earlier and up 12% organically, and adjusted EPS of $2.26, up 33%, a figure that includes $0.25 from IEEPA cost recovery. Its backlog reached $340 billion, including $164 billion of defense, and during the quarter it was awarded Tomahawk and AMRAAM multi-year undefinitized production contracts. RTX raised its 2026 outlook for adjusted sales to $97.0 billion to $97.5 billion, up from $95.0 billion to $96.0 billion, and for adjusted EPS to $7.65 to $7.75, up from $7.10 to $7.25.

"Demand for our products remains robust with over $81 billion of new commercial and defense awards, resulting in a record backlog of $340 billion," said RTX Chairman and CEO Chris Calio.

Northrop Grumman Corporation (NYSE: NOC)

Northrop Grumman reported third-quarter sales of $11.1 billion, up 7%, and diluted EPS of $7.89. Net awards totaled $16.4 billion for a book-to-bill ratio of 1.5x, and backlog totaled $109.6 billion. The company raised its 2026 guidance for MTM-adjusted EPS to $29.35 to $29.75, from $28.60 to $29.10, and for segment operating income to $4.94 billion to $5.04 billion, from $4.85 billion to $5.00 billion.

"In a complex world with the growing need for solutions that scale and perform, our customers continue to turn to Northrop Grumman, and we are delivering with urgency and innovation," said Kathy Warden, chair, chief executive officer and president of Northrop Grumman.

GE Aerospace (NYSE: GE)

GE Aerospace reported third-quarter total orders of $19.0 billion, up 49%, adjusted revenue of $13.3 billion, up 18%, and adjusted EPS of $2.25, up 36%. Its Defense & Propulsion Technologies segment booked orders of $4.3 billion, up 18%, on revenue of $3.5 billion, up 7%, and signed a contract worth up to $2.9 billion to provide ongoing support for the F414 engines powering the U.S. Navy's F/A-18 and EA-18G fleets. The company raised its 2026 guidance for adjusted EPS to $8.00 to $8.10, from $7.65 to $7.85, and for free cash flow to $9.1 billion to $9.4 billion, from $8.9 billion to $9.2 billion.

"We delivered strong results this quarter as solid demand drove orders up 49%, with strength in commercial services up 23%, total revenue up 18% and EPS up 36%," said GE Aerospace Chairman and CEO H. Lawrence Culp, Jr.

Lockheed Martin Corporation (NYSE: LMT)

Lockheed Martin will publish its third-quarter results before the market opens on Thursday, October 22, followed by a webcast at 8:30 a.m. ET. In its second-quarter report in July, the company posted a record backlog of $230 billion, inclusive of the multi-year contract to produce THAAD interceptors, and raised its 2026 outlook for sales to approximately $79.75 billion to $81.75 billion, from $77.5 billion to $80.0 billion, and for diluted EPS to approximately $29.95 to $30.65, from $29.35 to $30.25.

"We are delivering on our strategy, achieving a higher trajectory for our business and giving us confidence to raise our full year financial guidance," Lockheed Martin Chairman, President and CEO Jim Taiclet said in July.

L3Harris Technologies, Inc. (NYSE: LHX)

L3Harris will release its third-quarter results before the market opens on Thursday, October 29, with an earnings call at 10:30 a.m. ET. In its second-quarter report in July, the company posted orders of $7.3 billion and a book-to-bill of 1.2x that increased backlog to a record $42 billion, and it raised its 2026 guidance for revenue to $23.2 billion to $23.7 billion, from $23 billion to $23.5 billion, and for EPS to $11.80 to $12.00, from $11.40 to $11.60.

"Our purpose-built portfolio and focus on execution drove outstanding second quarter results," said Christopher Kubasik, Chairman and CEO of L3Harris, in July.

Defense stocks moved in both directions on Tuesday's reports, and two more contractors are still to come. Learn to read the setups behind moves like these with the free Stock Preachers guide, plus The Roadmap market reports, at equity-insider.com/.

Contact Information:

Media Contact: [email protected]

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is not a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.

This article is independent news commentary. Equity Insider is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. MEL has not been paid by any company mentioned in this article. MEL and its owners, operators, directors, and affiliates do not currently own any shares of the companies mentioned in this article, but reserve the right to, and will, buy and sell shares of those companies at any time without further notice. Daily price changes are from the October 19, 2026 close to the October 20, 2026 close based on Stock Analysis data. Company guidance, backlog figures and scheduled reporting dates are as stated by the companies and may change. Information is drawn from company news releases and filings, government and industry data, published reporting and third-party data believed to be reliable, but its accuracy is not guaranteed. Investing in securities carries risk, including the loss of some or all of your investment. This document is governed by the laws of Ireland.

SOURCE Equity Insider

Share this article

Financial Services Executive Duncan Niederauer Elected to Bob Woodruff Foundation Board of Directors

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- The Bob Woodruff Foundation announced Monday that Duncan Niederauer has been elected to a three-year term on the Foundation's Board of Directors. Niederauer's 40-year financial services career includes senior executive roles at NYSE Euronext and Goldman Sachs. He is the co-founder and vice chairman of Transcend Capital Advisors, an independent wealth management firm. Niederauer also co-founded the fintech venture fund Communitas Capital Partners, where he co-chairs the firm's investment committee.

Niederauer has served for more than a decade on the Foundation's Leadership Council, where he was instrumental in early strategy and development of its Got Your 6 Network.

"Duncan brings a lifetime of experience in financial services and organizational management to our Board," said Anne Marie Dougherty, CEO of the Bob Woodruff Foundation. "We know Duncan from his longtime advocacy for our nation's veterans and from his significant Leadership Council contributions to the development of our Got Your 6 Network. His expertise and perspective will have an immediate impact as we execute on our ambitious 2030 growth strategy."

"Few things are more important to me than how our country treats its veterans and military families," said Duncan Niederauer. "I've had a chance to watch up close over the last decade as this foundation has grown to operate the largest network of veteran support organizations outside of the VA. There's a real responsibility that comes with that success, and I look forward to contributing my experience in the C-suites and boardrooms of organizations key to the financial wellbeing of millions of Americans. I may be new to the Board, but I'm not new to the mission or to understanding what makes this foundation so special."

About Duncan Niederauer

Duncan Niederauer is the former CEO of NYSE Euronext, where he served from 2007 to 2014. Prior to that he was a partner of Goldman Sachs, & Co., where he worked from 1985 to 2007. His career has been defined by his ability to innovate, advise, and successfully execute traditional and disruptive business models. A leading figure in the industry, Duncan has received numerous career distinctions and honors, most notably the John C. Whitehead Award for Leadership. In 2013, he was recognized as an Honorary Commander of the British Empire (CBE) by her majesty, Queen Elizabeth II, for his efforts to advance the peace process in Northern Ireland.

Duncan earned an MBA from Emory University and a BA from Colgate University. He and his wife, Alison, led the Newmark School's "Destination of Promise" campaign, which built a state-of-the-art school for children with autism and related disabilities in Scotch Plains, New Jersey.

About the Bob Woodruff Foundation

The Bob Woodruff Foundation was founded by ABC News reporter Bob Woodruff and his family after Bob was wounded by a roadside bomb while covering the war in Iraq. The Foundation funds proven organizations delivering services to veterans, service members and their families in all 50 states. Bob Woodruff Foundation's Got Your 6 Network of 500 boots-on-the-ground partner organizations provides physical and mental health care, housing and legal assistance, disaster relief, and job placement services to the military community. The Foundation has funded $228 million in proven veteran programs and services since it opened its doors in 2006. More than two million Americans in the military community receive care or support from a Got Your 6 Network partner each year, building on the Foundation's commitment to always have the backs of those who have served.

CONTACT: Eric Phillips, Bob Woodruff Foundation, [email protected]

SOURCE Bob Woodruff Foundation

Share this article

Manulife and UpLink announce winners of the 'Shaping Canada's Longevity Advantage' Challenge

Ten innovators selected for solutions that help Canadians live longer, healthier, more financially secure lives

The challenge is an initiative of Manulife's Longevity Institute, driving solutions for a longer‑living Canadian society

TORONTO, Oct. 21, 2026 /CNW/ -- Manulife, in collaboration with UpLink, the World Economic Forum's early-stage innovation initiative, today announced the winners of the 'Shaping Canada's Longevity Advantage Challenge,' the third and final challenge in a multi-year partnership focused on advancing longevity innovation. Open to innovators from Canada and around the world, the challenge sought practical, near-term solutions that can improve health, financial resilience and social connectedness for Canadians while fostering purpose and opportunity across generations.

As Canadians live longeri and more multi-stage lives, new solutions are needed to help people thrive across those additional years through better health, stronger financial resilience, meaningful social connection and a greater sense of purpose. The winning cohort showcases innovative approaches to helping Canadians navigate longer lives while supporting caregivers, families and communities.

The 10 winners of the 'Shaping Canada's Longevity Advantage Challenge' are:

- Amical (Quebec City, Canada), which delivers an AI-powered companion through a familiar telephone interface to support older adults and people living with cognitive disorders.

- Childfree Trust (Mount Juliet, United States), which provides estate planning, fiduciary and emergency response services designed for childfree individuals and solo agers.

- Clay Financial (Toronto, Canada), which enables older Canadians to unlock home equity through Home Equity Sharing Agreements without taking on debt or monthly payments.

- Cosm Medical (Toronto, Canada), which uses AI, software and 3D printing to create personalized pelvic health devices that help people maintain active and independent lives.

- Idem (Montreal, Canada), which develops connected cognitive aids that support independence and care coordination for people living with dementia.

- LINK Plans (Calgary, Canada), which helps expand access to workplace retirement savings plans through financial institutions and payroll providers.

- MIMOSA Diagnostics (Toronto, Canada), which uses portable imaging technology to detect pressure injuries before visible skin breakdown occurs.

- Myant Health (Mississauga, Canada), which transforms everyday clothing into continuous health monitoring tools through smart textile technology.

- Pontosense (Toronto, Canada), which uses AI-powered wireless sensing technology to detect falls, monitor vital signs and support independent living without cameras or wearables.

- PragmaClin (St. John's, Canada), which has developed an AI-powered neurological assessment platform for people living with Parkinson's disease.

"Living longer is one of the greatest opportunities of our time, but it also challenges us to think differently about health and financial wellbeing," said Patrick Graham, President & CEO, Manulife Canada. "The innovators recognized through this challenge are tackling some of the biggest questions that come with living longer: how we stay healthier for longer and how we build greater financial resilience. These are big challenges, and we need bold ideas to take them on."

Nearly 40 per cent of Canadians are already over the age of 50ii, while many are balancing their own health and financial goals alongside caregiving responsibilities for aging parents and loved ones. At the same time, insights from the National Institute on Ageing's Ageing in Canada Survey, conducted by the NIA with support from Manulife, shows 43 per cent of older Canadians are at high risk of social isolation and only 29 per cent feel they can afford to retire, highlighting the need for innovative solutions that improve health, financial resilience and social connection. The challenge focused on three key areas: helping people plan for and navigate longer lives, supporting prevention and care coordination, and strengthening belonging and intergenerational connection.

"Longevity is reshaping how people work, save, care for others, and prepare for retirement," said Paul Lorentz, President and Chief Executive Officer, Manulife Wealth & Asset Management. "Canada has an opportunity to lead by advancing solutions that help people remain healthy, connected, and financially resilient throughout longer lives. This winning cohort demonstrates how innovation can turn that opportunity into meaningful action for individuals, families and communities."

The winning ventures will gain access to UpLink's global innovation ecosystem, connecting them with corporates, investors, policymakers and other partners that can help accelerate their growth and scale their impact.

"Through the World Economic Forum's UpLink and Global Longevity Innovation Initiative, we are proud to partner with Manulife to source and scale early-stage ventures that empower people to lead healthier, more financially resilient and fulfilling lives," said John Dutton, Head of UpLink, World Economic Forum. "With Manulife's support, this new cohort builds on the progress of previous editions and highlights how breakthrough solutions can help drive transformation across Canada's health, financial and care systems, strengthening people's ability to plan for and navigate longer lives."

The Shaping Canada's Longevity Advantage Challenge builds on Manulife's multi-year partnership with UpLink, announced at the World Economic Forum Annual Meeting in Davos in 2024. The partnership is designed to help identify and scale innovations that support healthier, more financially resilient and fulfilling lives as global populations age. This challenge follows the successful 'Prospering in Longevity Challenge' in 2024 and 'Innovating for Asia's Demographic' Future Challenge in 2025.

This initiative underscores the efforts of the Manulife Longevity Institute, a global research, thought leadership, innovation, advocacy, and community investment platform that is driving action to help people thrive at every age. To learn more about Manulife's longevity efforts and the work of the Manulife Longevity Institute, visit manulife.com.

About Manulife

Manulife Financial Corporation is a leading international financial services provider, headquartered in Toronto, Canada. Anchored in our ambition to be the number one choice for customers, we operate as Manulife across Canada and Asia, and primarily as John Hancock in the United States, providing financial advice, insurance and health solutions for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment solutions, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2025, we had more than 37,000 employees, over 106,000 agents, and thousands of distribution partners, serving over 37 million customers with operations across 25 markets globally. We trade as 'MFC' on the Toronto, New York, and Philippine stock exchanges, and under '945' on the Hong Kong stock exchange. Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com.

About Manulife Longevity Institute

The Manulife Longevity Institute is a global research, thought leadership, innovation, advocacy, and community investment platform to drive action that can help people live longer, healthier, and more financially secure lives. Underpinned by a $350 million signature commitment, its focus is on helping people extend their healthy years, promoting greater financial resilience for all. As a global insurer, retirement plan provider, and asset manager, Manulife is uniquely placed to help lead this change. The Institute's work will support Manulife's Impact Agenda strategy by investing in organizations that are growing the longevity economy, convening research collaborations with leading academic institutions and think tanks, and producing thought leadership to advance awareness and action on the issues impacting populations as they age. The Institute will be known as the John Hancock Longevity Institute in the United States. The actions of the Institute will be guided by a Steering Committee of members of Manulife's Executive and Global Leadership Teams and in partnership with a robust ecosystem of partners and experts who champion longevity across Canada, Asia, and the US.

For more information, please visit Manulife.com/Longevity.

About UpLink

UpLink, the World Economic Forum's early-stage innovation engine, connects purpose-driven innovators with the partnerships, resources and capital they need to scale solutions for the markets and economies critical to a resilient, sustainable and prosperous world. UpLink envisions a future where profit and purpose go hand in hand -- where innovation drives competitiveness, inclusion, and long-term value, where economic growth uplifts people while restoring the planet, and where resilience is the foundation of thriving, future-proof economies. For further information, click here.

Media contact

Manulife:

Emily English

[email protected]

647-544-2800

SOURCE Manulife Financial Corporation

Share this article

- Multi-center, placebo-controlled study will assess the combination in adults with persistent symptoms after antibiotic treatment for Lyme disease

- Trial design informed by recent research linking residual bacterial proteins to immune dysregulation in a subset of patients

HAYWARD, Calif., Oct. 21, 2026 /PRNewswire/ -- HealthBio, Inc., a biotechnology company developing novel immune-reset therapies for inflammatory disease, today announced the initiation of its multi-center, randomized, double-blind, placebo-controlled clinical trial (HBT-002; IND185316) evaluating its lead compound Inflamexa™, in adults with post-treatment Lyme disease syndrome (PTLDS).

The study will enroll approximately 252 participants across at least six U.S. sites, which include major medical centers in Lyme endemic regions. Participants will be randomized in equal numbers to receive the combination or matching placebos for 12 weeks. The primary endpoint is fatigue at week 24, assessed using the modified Fatigue Severity Scale (FSS-11), allowing evaluation beyond the treatment period. Secondary assessments will examine fatigue at week 12, quality of life, overall symptom burden, physical, mental, and social health, and safety. Exploratory analyses will evaluate immune biomarkers. The trial is not yet open and is not recruiting participants.

The trial builds on HealthBio's ongoing evaluation of the same patented immune reset therapy in Long COVID and on a recently posted preprint (https://doi.org/10.64898/2026.09.24.26363601) examining persistent Borrelia burgdorferi proteins in white blood cells called monocytes in patients with PTLDS. That work detected bacterial proteins months to years after antibiotic treatment in the absence of active bacterial transcription and identified associated inflammatory gene-expression patterns.

New Insights into Immune Dysregulation After Lyme Disease

Researchers from HealthBio and academic collaborators analyzed isolated CD14-positive and CD16-positive monocytes from patients with persistent symptoms following antibiotic Lyme disease treatment. Mass spectrometry detected two bacterial proteins, FlaB and OspC, in samples from multiple participants, months to years after antibiotic treatment.

"These findings give us a biological hypothesis to investigate, whether bacterial material remaining after treatment contributes to persistent immune dysfunction," said Bruce K. Patterson, M.D., co-founder and chief executive officer of HealthBio. "Our planned randomized, placebo-controlled trial is designed to evaluate whether targeting immune pathways with Inflamexa™ can improve symptoms in people with PTLDS. Connecting immunological discoveries with rigorous clinical evaluation is central to HealthBio's approach."

About HealthBio

HealthBio, Inc., a biotechnology company developing diagnostic and therapeutic approaches for chronic inflammatory and immune-mediated diseases. Its research examines persistent immune dysregulation and translates biological insights into potential treatments for clinical evaluation using machine learning and AI-based precision diagnostics. HealthBio is initially focused on precision immune modulation of neglected diseases, including Long COVID, Myalgic Encephalomyelitis-Chronic Fatigue Syndrome (ME-CFS) and Chronic Lyme Disease. The company aims to improve diagnosis, advance new science, and innovate new medicines for these historically minimally characterized diseases. For more information or investment inquiries, please contact us at www.healthbio.com.

Investor Contact:

Brian Brothen

[email protected]

SOURCE Healthbio Inc

Share this article

Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect

- Publication of first ever head-to-head comparison of gut microbiome changes associated with novel oral preclinical PolC (pol IIIC*) inhibitors to linezolid in a murine neutropenic thigh infection model

- Structural molecular modification of molecules related to ibezapolstat (IBZ) improved solubility and systemic exposure of novel Pol IIIC inhibitors with all three tested Pol IIIC inhibitors reduced MRSA burden in a neutropenic mouse thigh model

- Pol IIIC inhibitors in this study maintained high gut microbial diversity, as well as preserved microbiome metabolic function, in contrast to the marked disruption shown by linezolid

- Pol IIIC inhibitor compounds specifically preserved anaerobic microbiome components and metabolism, whereas linezolid induced depletion and disruption of healthy anaerobic bacterial communities

- Acurx's DNA pol IIIC inhibitor preclinical product candidates are FDA QIDP and Fast-Track eligible and target Gram-positive infections classified as Serious Threat priorities by CDC

STATEN ISLAND, N.Y., Oct. 21, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for serious and life-threatening bacterial infections, today announced publication in the ASM (American Society for Microbiology) Microbiology Spectrum journal of results of a study entitled: The effects of novel oral preclinical PolC inhibitor antibiotic candidates on the gut microbiome in a murine thigh infection model. These findings confirm in vivo antibacterial activity at tested doses while suggesting that further structural or dosing optimization may enhance tissue-level efficacy. Compared with oral linezolid, a commonly used oral therapy for gram-positive infections, orally dosed Pol IIIC inhibitors demonstrated a consistent class characterized by preservation of a Bacteroidota-dominant murine gut community and maintenance of anaerobic metabolic pathways. These experiments also highlight the importance of microbiome-informed antibiotic evaluation in preclinical studies.

Kevin Garey, PharmD, MS, FIDSA and Principal Investigator for microbiology and microbiome aspects of Acurx's DNA pol IIIC program and the Robert L. Boblitt, Endowed Professor in Drug Discovery at the University of Houston College of Pharmacy is the lead author and commented on the significance of the data: "Discovering highly selective antibacterial agents that specifically target systemic bacterial pathogens while avoiding the eradication of trillions of health-promoting bacteria in our gut microbiome remains a "Holy Grail" of antibiotic development. Work in our laboratory with Acurx's novel DNA pol IIIC inhibitors has advanced this work by demonstrating favorable gut microbiome-sparing effects of this novel class of antibiotics. It further emphasizes the value of incorporating microbiome profiling into the earliest phases of new antibiotic clinical research programs."

Robert J. DeLuccia, Executive Chairman of Acurx, stated: "Acurx is at the forefront of pioneering Antimicrobial Stewardship with antibiotics by discovering and developing innovative narrow-spectrum antibiotics which cause minimal gut dysbiosis. This Microbiome Stewardship dimension, which we believe should be fundamental to driving today's drug discovery and development process, is emerging as a new standard in the field of human anti-infective research".

Acurx's portfolio of preclinical compounds include clinical applications for infections caused by MRSA such as: ABSSI, Hospital Acquired and Ventilator Acquired Bacterial Pneumonia, bacteremia with or without sepsis and/or endocarditis, bone and joint and diabetic foot infections and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).

*Pol IIIC is alternative nomenclature for Pol C

The publication is available on the Acurx Pharmaceuticals website www.acurxpharma.com

ASM publication: https://pubmed.ncbi.nlm.nih.gov/42885945/

About ASM (American Society for Microbiology) Spectrum

Microbiology Spectrum® is an online-only, fully open-access journal that publishes research from all domains of basic, applied, and clinical microbial sciences. Rather than making subjective evaluations of potential impact, Microbiology Spectrum publishes research studies that are of high technical quality and are useful to the community. All decisions are made by an international and diverse editorial board that fully represents the microbiology research community.

About MRSA (Methicillin-Resistant Staphylococcus Aureus)

While ibezapolstat for the treatment of C. difficile Infection (CDI) is ready to advance to Phase 3 international pivotal trials, Acurx's R&D platform has sustainability for additional new product candidates from its pipeline of systemic (oral and IV) antibiotics to treat infections caused by other susceptible and antimicrobial resistant bacteria, including infections caused by MRSA. The CDC estimates ~323,700 hospital cases of MRSA infections annually with ~10,600 deaths. In a recent CDC surveillance study in hospitalized patients in the US, MRSA accounted for 52% of all infections, almost twice as many as MDR Gram-negative infections.

Clinical applications for these infections include: ABSSI, Hospital Acquired and Ventilator Acquired Bacterial Pneumonia, bacteremia with or without sepsis and/or endocarditis, bone and joint, diabetic foot infections. Acurx's DNA pol IIIC inhibitor preclinical product candidates are FDA QIDP and Fast-Track eligible and target Gram-positive infections classified as Serious Threat priorities by CDC.

About the Neutropenic Mouse Model

The purpose of the murine thigh MRSA infection model was to evaluate the in vivo efficacy of the PolC inhibitor compounds using linezolid as a control. Animal experiments were conducted at NeoSome Life Sciences, an American Association for the Accreditation of Laboratory Animal Care-accredited facility. All experiments were approved by the NeoSome Institutional Animal Care and Use Committee (protocol number NLS24-011). Female CD-1 mice (Charles River Laboratories) were rendered neutropenic by two intraperitoneal doses of cyclophosphamide and acclimated for 5 days prior to study initiation. Mice were housed four per cage with ad libitum access to food and water. All animals were inoculated intramuscularly in the right rear thigh with a prepared bacterial suspension containing MRSA strain BAA-1717 (USA 300) at time 0, achieving a final inoculum of 1.8 × 105 colony-forming unit (CFU) per mouse thigh. Antibiotic treatment began 1 h post-infection, with each cage serving as an independent experimental unit receiving a single drug–dose combination.

Acurx previously announced that the first patient has been enrolled in its new clinical trial (PATHFINDER) in patients with multiply recurrent C. difficile Infection (rCDI). This new, fully funded,PATHFINDER clinical trial is a pilot trial in approximately 20 patients with multiply-recurrent CDI (at least three episodes over the past 12 months) and will support filing of a U.S. NDA (New Drug Application) based on a single Phase 3 trial.

The PATHFINDER Phase 2 multicenter, open-label, single-arm study evaluates the efficacy and safety of ibezapolstat in the treatment and reduction of recurrence of CDI in patients who have experienced at least 3 episodes of CDI within the past 12 months. Participants will be treated with IBZ for 14 days and assessed for Clinical Cure (Day 16), Sustained Clinical Cure (Day 42), rate of CDI recurrence (to Week 24), and Extended Clinical Cure (to Week 24).

https://clinicaltrials.gov/study/NCT07513285?term=acurx&viewType=Card&rank=2

Separately, the planned ASPIRE trial is of non-inferiority design with the primary efficacy analysis in the Modified Intent-To-Treat (mITT) population and will result in approximately 550 subjects in the mITT population, randomized in a 1:1 ratio to either ibezapolstat or standard-of-care vancomycin. The ASPIRE trial will be conducted when the Company has sufficient resources from public or private partnership(s) to fund this trial.

Acurx previously announced the successful outcome of a Type C Meeting conducted with FDA on July 13, 2026 to discuss ibezapolstat's Phase 3 clinical program and scope of its planned NDA. The Agency stated that it is open to further discussion at a Pre-NDA Meeting regarding the possibility of submitting an NDA with only a single Phase 3 trial, depending on the totality of the clinical data plus any other supportive data that Acurx may generate by that milestone. The Agency noted that determination of acceptability of one Phase 3 clinical trial for an NDA is made on a case-by-case basis, taking into consideration such factors as the magnitude, consistency, and overall robustness of the efficacy results; generalizability of the results to the US population; relevance of the results to US patient care and clinical practice guidelines; Phase 2 data; and an adequate safety database. The Agency acknowledged Acurx's planned clinical trial in recurrent CDI (rCDI) and noted the data from this rCDI trial, if successful, would support an NDA submission. If the IBZ-ASPIRE trial does not meet these criteria, then a second trial consistent with the agreement reached at the end of Phase 2 (EOP2) meeting on April 27, 2024, is recommended.

The currently planned IBZ-ASPIRE trial is of non-inferiority design with the primary efficacy analysis in the Modified Intent-To-Treat (mITT) population. This will result in approximately 550 subjects in the mITT population, randomized in a 1:1 ratio to either ibezapolstat or standard-of-care vancomycin.